Koers Xintela AB (publ) Nasdaq Stockholm
Aandelen
SE0007756903
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | 78K 7,13K 6,67K | Marktkapitalisatie | 148 mln. 13,52 mln. 12,65 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -66 mln. -6,03 mln. -5,64 mln. | Nettowinst (verlies) 2023 | -54 mln. -4,94 mln. -4,62 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 8,34 mln. 763K 713K | Nettoliquiditeiten 2023 | 7,81 mln. 714K 668K | EV/omzet 2023 | 1.797 x |
K/w-verhouding 2022 |
-1,33
x | K/w-verhouding 2023 |
-2,1
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 31,28% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 67 | 01-01-09 | |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 01-01-13 |
Thomas Areschoug
PRN | Corporate Officer/Principal | 52 | 01-03-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lars Olof Hedbys
BRD | Director/Board Member | 67 | 01-01-21 |
Chairman | 67 | 01-01-11 | |
Director/Board Member | 64 | 01-01-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |